论文部分内容阅读
组织型纤溶酶原激活剂(t-PA)多用于治疗急性心肌梗塞,而对急性缺血性脑卒中的溶栓作用研究较少,其中有伴发颅内血肿的报道。本文回顾性分析使用t-PA的94例急性缺血性脑卒中患者,以了解应用t-PA治疗时发生颅内血肿的相关因素。其中,74例患者在发病90min内接受t-PA治疗,结果有3例(4％)出现颅内血肿,另20例患者在91～180min内接受t-PA治疗,结果有2例(10％)出现颅内血肿。t-PA剂量≥0.90mg/kg的72例中仅1例(1％)发生颅内血肿。舒张压≥13.3kPa(100mmHg)的22例患者中有4例(18％)发生颅内血肿,而舒张压在13.3kPa以下的72例患者中仅1例(1％)发生颅内
Tissue-type plasminogen activator (t-PA) are mostly used for the treatment of acute myocardial infarction, and the thrombolytic effect of acute ischemic stroke less research, of which there are reports of intracranial hematoma. This paper retrospectively analyzed 94 patients with acute ischemic stroke using t-PA to understand the relevant factors of intracranial hematoma in the treatment of t-PA. Of the 74 patients who received t-PA within 90 min of onset, 3 (4%) had intracranial hematoma and the other 20 patients received t-PA within 91 to 180 min (2%, 10% ) Intracranial hematoma. Intracranial hematoma occurred in only 1 (1%) of the 72 patients who had a t-PA dose of 0.90 mg / kg. Intracranial hematoma occurred in 4 (18%) of the 22 patients with a diastolic blood pressure> 13.3 kPa (100 mmHg) and only 1 (1%) in 72 patients with a diastolic blood pressure below 13.3 kPa developed intracranial